GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Pei Wang, PhD
Eureka Therapeutics Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Taiwan University Cancer Center
Taipei, Taiwan
Chiun Hsu, MD, PhDRecruiting
- City of Hope
Duarte, California, United States
Daneng Li, MDRecruiting - Kansas University Medical Center, Principal Investigator:
Westwood, Kansas, United States
Completed - Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Completed - Montefiore Einstein Comprehensive Cancer Center
The Bronx, New York, United States
R. Alejandro Sica, MDRecruiting - Oregon Health and Sciences University
Portland, Oregon, United States
Adel Kardosh, MDRichard Maziarz, MDRecruiting - University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas, United States
David Hsieh, MDFarrukh Awan, MDRecruiting - Fred Hutchinson Cancer Center, University of Washington
Seattle, Washington, United States
William Harris, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Mar 2022
- Primary completion
- 31 Dec 2027
- Completion
- 31 Dec 2027
- Last update posted
- 9 Jun 2026
- Registered enrollment
- 60
- Registry id
- NCT04864054
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.